Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.

por Trimoreau, F, François, B, Desachy, A, Besse, A, Vignon, P, Denizot, Y
Publicado 2000

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

por Besse, L, Kraus, M, Besse, A, Bader, J, Silzle, T, Mehrling, T, Driessen, C
Publicado 2017

Personalized medicine approach confirms a milder case of ABAT deficiency

por Besse, A., Petersen, A. K., Hunter, J. V., Appadurai, V., Lalani, S. R., Bonnen, P. E.
Publicado 2016

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

por Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Publicado 2018

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

por Soriano, G P, Besse, L, Li, N, Kraus, M, Besse, A, Meeuwenoord, N, Bader, J, Everts, B, den Dulk, H, Overkleeft, H S, Florea, B I, Driessen, C
Publicado 2016

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY C...

por Zhou, X., Besse, A., Peter, J., Steinhardt, M. J., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Xiao, X., Hornburger, H., Haertle, L., Mendez Lopez, M., Munawar, U., Riedel, A., Han, S., Maurits, E., Overkleeft, H. S., Florea, B., Einsele, H., Kortüm, K. M., Driessen, C., Besse, L., Rasche, L.
Publicado 2023